Anika Therapeutics Inc Stock Price, News & Analysis

Anika Therapeutics (NASDAQ: ANIK) announced the granting of non-statutory stock options for 10,428 shares and restricted stock units for 4,699 shares to three new non-executive employees as part of its 2021 Inducement Plan. The options, with an exercise price of $31.50, will vest over three years, contingent upon continued service. The RSUs also vest in three equal installments over the same period. This action was made to incentivize the new hires and did not require stockholder approval.

Anika Therapeutics (NASDAQ: ANIK) is set to release its fourth quarter and year-end 2021 financial results on March 8, 2022, after market close. The company will also host an investor conference call at 5:00 p.m. ET the same day to discuss these results and business highlights. Interested parties can join the call by dialing the provided numbers or accessing a live audio webcast through the Investor Relations section of Anika's website, where a slide presentation will also be available.

Anika Therapeutics (NASDAQ: ANIK) announced the grant of non-statutory stock options for 1,069 shares and restricted stock units (RSUs) for 468 shares to a new non-executive employee on December 1, 2021. The stock options have an exercise price of $38.53, equal to the closing price on the grant date, and will vest over three years. The RSUs will also vest in three equal installments. These grants were part of the 2021 Inducement Plan and serve as a material inducement to employment.

Anika Therapeutics (NASDAQ: ANIK) announced the participation of Dr. Cheryl Blanchard and Michael Levitz in upcoming investor conferences. They will present at the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 29 to December 2, 2021, with a pre-recorded presentation available on November 22, 2021. Additionally, they will attend the Stephens Annual Investment Conference in Nashville, TN, on December 3, 2021, featuring a live presentation at 11:00 a.m. CT. Webcasts of both events will be accessible on Anika's investor relations website.

Anika Therapeutics (NASDAQ: ANIK) reported a 25% year-over-year revenue growth for Q3 2021, reaching $39.5 million, driven primarily by a 42% increase in Joint Pain Management revenue. Despite operational successes, the company revised its 2021 revenue growth outlook to 9-11% due to COVID-19 impacts. Adjusted net income remained stable at $0.05 per share. Gross margin stood at 58%, with an adjusted gross margin of 66%. The company maintains its long-term strategy to double revenues by 2024.

Anika Therapeutics has appointed Sheryl Conley as an independent director to its Board, effective October 28, 2021. With over 35 years in the orthopedic field, including roles at OrthoWorx and Zimmer, Conley's expertise in marketing, sales, and product development is expected to enhance Anika's strategic objectives. This appointment increases the number of independent directors to seven, supporting Anika's goal to become a leading joint preservation company. Conley also holds positions on the boards of other healthcare companies, further showcasing her industry influence.

Anika Therapeutics, Inc. (NASDAQ: ANIK) plans to release its third quarter 2021 financial results post-market on November 4, 2021. The company will hold an investor conference call at 5:00 p.m. ET the same day to discuss financial results and business highlights. Stakeholders can participate via dial-in or through a live audio webcast available on Anika's website. The call will be archived for later access. Anika specializes in joint preservation through innovations in orthopedic care, focusing on osteoarthritis management and regenerative solutions.

Anika Therapeutics (NASDAQ: ANIK) has launched its WristMotion® Total Wrist Arthroplasty (TWA) System at the ASSH 2021 annual meeting, aimed at treating wrist arthritis. This innovative system enhances carpal stability and allows for natural wrist motions, offering an alternative to traditional wrist fusion methods. Early clinical feedback has been positive, with over 2,600 cases of related systems performed since 2015. The TWA System is designed in collaboration with leading surgeons and aims to restore wrist function and improve patient mobility.

Anika Therapeutics (NASDAQ: ANIK) has received 510(k) clearance from the FDA for its Tactoset® Injectable Bone Substitute. This clearance allows Tactoset to augment hardware and support bone fragments during surgical procedures. With this expanded indication, the addressable market now includes augmentation of suture anchor fixation, a significant growth area for Anika. Tactoset, launched in Q4 2019, is a calcium phosphate-based biocompatible bone graft that enhances surgical outcomes. Anika plans to actively market this indication starting in October 2021.